Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (July 2019)
50 slides from Evogene's investor presentation, Jul 31, 2019
Slide 1: Evogene at a Glance
Evogene at a Glance…July, 2019 Ofer Haviv, President & CEO
Slide 2: Safe Harbor Statement
Safe Harbor Statement * This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or i
Slide 3: Agenda
What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *
Slide 4: What We Do
What We Do… * We revolutionize the product development process in life-science based markets… …through the use of a unique Computational Predictive Biology (CPB) platform
Slide 5: Agenda: Our technology – the CPB platform
What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *
Slide 6: The Challenge - Product Development Common Practice
The Challenge - Product Development Common Practice * Successful Product Launch Extremely low probability of successLong time to market High development costs Limited ‘next generation’ products in pipelines Candidates mainly addressing the first criterion Product Definition Efficacy Stability Shelf-
Slide 7: The Desired Solution
The Desired SolutionCandidates with the highest probability of success * Candidates addressing the majority of product criteria at Stage Zero Increasing probability of successReducing time to marketReducing budget Successful Product Launch
Slide 8: Evogene’s Unique Product Development Approach
Evogene’s Unique Product Development Approach * Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at ‘Stage Zero’ Successful Product Launch The CPB
Slide 9: Prediction of Candidates for Life-Science Based Products
Microbes Prediction of Candidates for Life-Science Based Products * Genetic Elements Small Molecules \\ \\ Prism Plant genes – associated to specific plant traits Plant edits – edits to control gene expression Genomic markers – genomics tools to assist breeders* Bacterial genes – toxins for insects
Slide 10: Agenda: Target markets
What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *
Slide 11: Targeted Markets
Targeted Markets * Red - Human HealthMedical CannabisPharmaceutical industryMedical applicationDiagnostics Green - AgricultureAg-ChemicalsSeedsAg-BiologicalsPrecision AgLivestockBiomaterialsEnergy Blue - AquamarineAquacultureHealth White- IndustrialIndustrial applicationPolymersEnzymesBacteria Red W
Slide 12: Agenda: Corporate structure & activities
What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *
Slide 13: Corporate Structure & Activities
Corporate Structure & Activities * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecti
Slide 14: Main Collaborations
Main Collaborations * Ag Biologicals Seed Traits (division) Medical Cannabis Human Microbiome Ag Chemicals Castor Oil Agriculture Human Health Industrial Applications CPB platform 100% 100% 100% 90% 100% 100% CASA
Slide 15: Milestone Roadmap
Milestone Roadmap * 2019 Complete two cannabis growth cycles Complete semi-commercial field trials 2020 Enter pre-clinical trials in 2 additional programs; positive results in at least one study Complete first pre-clinical study in oncology Advance product pipeline in wheat bio-stimulants Enter new
Slide 16: Agenda: Summary
What we do…Our technology – the CPB platform Target marketsCorporate structure & activitiesSummary- Annex I: Subsidiary Overview- Annex II: Financial Fundamentals Agenda *
Slide 17: Evogene at a Glance - Summary
Evogene at a Glance… Summary Main collaborations with world-leading companies : Our technology – the CPB platform:Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of p
Slide 18: Thank You!
Evogene at a Glance…July, 2019 Ofer Haviv, President & CEO Thank You! Contact:investors@evogene.comT: +972 8 931 1963
Slide 19: Annex I: Subsidiary Overview
* Annex I: Subsidiary Overview
Slide 20: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 21: AgPlenus (Ag-Chemicals) - Mission & Products
AgPlenus (Ag-Chemicals) - Mission & Products * Herbicides –Market size: $25B* (2018), growing market need for novel herbicides with improved safety profile and solution for increasing resistance to current herbicides Insecticides - Market size: $15B* (2018), growing market need for improved insectic
Slide 22: Business Model – Delivering De-Risked Lead Candidates
Business Model – Delivering De-Risked Lead Candidates * Discovery Lead Optimization Continued development & regulation Target Hit Lead Optimized Lead Commercial-level efficacySolid business case Commercial-level efficacySolid business caseSelective pre-regulatory data Indication for commercial-level
Slide 23: AgPlenus (Ag-Chemicals) - Pipeline
AgPlenus (Ag-Chemicals) - Pipeline * Discovery Lead Optimization Herbicides Novel model of action(non-selective/selective) Insecticides Novel site of actionbroad spectrum Fungicides Existing mode of actionoptimization Optimized lead Lead Hit Target 5 targets/sites Final product Continued development
Slide 24: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 25: Lavie Bio (Ag-Biologicals) - Mission & Products
Lavie Bio (Ag-Biologicals) - Mission & Products * Mission: Improve food quality, health and sustainability through the introduction of microbiome based ag-biologicals products Bio-Stimulant – Market size: $2B* (2016), Microbial based targeting yield improvement in row crops such as corn, wheatBio-Pe
Slide 26: Business Model
Business Model * Distribution channels A B Model A – Direct Market Access Model B – Market Access via partner Consolidated markets Partner Fragmented markets Co-development of corn bio-stimulants with Corteva
Slide 27: Lavie Bio (Ag-Biologicals) - Pipeline
Product program Application Discovery Early Dev. Dev.stage 1 Dev. stage 2 Commercialization Product Bio Stimulants Corn Yield improvement under normal & drought Seed treatment Wheat Yield improvement under normal & drought Seed treatment Bio Pesticides Fusarium and seedlings disease(Corn) Protect fr
Slide 28: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 29: Ag Seeds - Mission & Products
Ag Seeds - Mission & Products * Insect control traits- Lepidoptera, Coleoptera, HemipteraYield and environmental stress traits- Yield, drought, nitrogen usage efficiencyDisease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes Mission: Bring to market top-quality seeds with high-val
Slide 30: Insect Control
Insect Control * Diverse trait portfolio with novel Mode of Action ! Discover & develop novel proteins conferring resistance to key insects through new modes of action
Slide 31: Insect Control - Example
* STK is a major Cotton & Soybean pestNo trait solution in the marketEV040030208 is a member of a gene family, 1st hit in a potential ‘gold mine’ of additional novel insecticidal genes Confirmed protection from Southern Green Stinkbug (STK) in transgenic tomato in 3 experiments Insect Control - Exam
Slide 32: Yield and Environmental Stress Product Candidates
Corn Yield Drought Nitrogen use efficiency Soybean Yield Drought Yield and Environmental Stress Product Candidates* Discovery Phase 1 (POC) Phase IV (Pre -Launch) 18m-24m 1-2 years Phase 2 (Early Development) Phase 3 (Adv. Dev & Regulation) 1-2 years 4-6 year 2-4 year Crop Trait Partner Product * *T
Slide 33: Yield and Environmental Stress Collaboration Example: Bayer (Monsanto)
* Yield and Environmental Stress Collaboration ExampleBayer (Monsanto) Improvedseeds Gene discovery and trait optimization Development and commercialization Model plant validation Target plant validationand development CPB Collaboration period - 10 yearsObjective - improved seeds via biotechnologyCr
Slide 34: Disease Resistance Pipeline
Corn Fusarium stalk rot Soybean Asian Rust Banana Black Sigatoka Disease Resistance Pipeline: Discovery Phase 1 (POC) Phase IV (Pre -Launch) 18m-24m 1-2 years Phase 2 (Early Development) Phase 3 (Adv. Dev & Regulation) 1-2 years 4-6 year 2-4 year Crop Trait Partner Product * *Timeline according to i
Slide 35: Genome Editing Disease Resistance Example
Genome Editing Disease Resistance Example *
Slide 36: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 37: Biomica – Mission & Products
Biomica – Mission & Products * Mission: Discovery and development of novel therapiesfor microbiome-related human disorders using computational predictive biology Microbiome and small molecule based therapies for:Immuno-oncology (with ICI) – combination therapy for cancerMDRO (Multi Drug resistant or
Slide 38: Big Biopharma is Investing More Through Partnerships
Big Biopharma is Investing More Through Partnerships * Obesity and metabolic disease 2014 Inflammatorybowel disease 2013 Ulcerative Colitis 2013 Crohn’s disease 2016 Inflammatorybowel disease 2016 Inflammatorybowel disease 2017 Gastrointestinal indications 2017 Crohn’s disease 2014 Inflammatorybowel
Slide 39: Pipeline
Pipeline * Program Indication / Target Discovery Preclinical Phase 1 Phase 2 Approach Immuno-oncology (with ICI) BMC121 Combination Therapyfor NSCLC BMC127 Combination Therapyfor NSCLC MDRO BMC201 C. difficile toxin-B GI related disorders BMC426 IBS BMC321 IBD BMC322 IBD Biological Small Molecule
Slide 40: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 41: Canonic – Mission & Products
Canonic – Mission & Products * Mission: To develop and bring to marketmedical grade cannabis through a revolutionary genomic approach Innovative products to address key market needs: Products under development: MetaYield* - Increased metabolite yieldUnican* - Verified variety stabilityPrecise* - Tai
Slide 42: Business Model
Business Model * Seed production Varieties dev. Cannabis growth Formulation Distribution Canonic aims to develop elite cannabis varieties for commercialization of medical products directly or via partnerships Clinical validation & regulation Unique varieties Seeds Flowers Potential partnerships
Slide 43: Milestone Roadmap
Milestone Roadmap * Establishment of R&D growing facility Complete two cannabis growth cyclesEstablish agronomic protocols Build cannabis core collectionEstablish initial cannabis database 2019 First product trait demonstrated Complete three cannabis growth cyclesComplete establishment of proprietar
Slide 44: Corporate Structure
Corporate Structure * Ag BiologicalsBio StimulantsBio Pesticides Seed Traits (division)(i) Yield, ABST &Plant Disease(ii) Insect Control Medical CannabisHigh yield, stability & tailored medical indications Human MicrobiomeHuman Microbiome based Therapeutics Ag ChemicalsHerbicidesInsecticides Castor
Slide 45: Casterra – Mission & Products
Casterra – Mission & Products * Our mission: Providing stable supply for the growing market demand for castor oil Product:An integrated ag-solution for castor - proprietary castor seed varieties supported by novel agro-technical know-how and proprietary mechanical harvesting. Traditional cultivation
Slide 46: Business Model and Technological Position
Business Model and Technological Position * Crusher Grower + Partner Revenue sharing with oil producers Oil/Cake Seed production Industrial oil users Breeding technology & genomics Seed production Grower Crusher Product Industrial oil users Breeding technology & genomics Seed sales - Integrated solu
Slide 47: Pipeline
Pipeline * Portfolio Pipeline Adaptable to mechanical harvest, Concentrated ripening, Uniformity, High grade oil % 1st generation: CR -712 Gold Pre-commercial & mechanical Harvesting Yield trials & Growth Protocol Early screening Research / Pre-Breeding Israel - E1-E2 Target market – D1-D2 Commercia
Slide 48: Annex II: Financial Fundamentals
* Annex II: Financial Fundamentals
Slide 49: Key Financials – Balance Sheet
Key Financials – Balance Sheet * Thousand US $ 30.06.2019 31.12.2018 Current Assets 47,795 55,488 Long-Term Assets 5,659 3,206 Total Assets 53,454 58,694 Current Liabilities 4,713 5,431 Long-Term Liabilities 5,883 2,957 Total Shareholders Equity 42,858 50,306 Total Liabilities & Shareholders Equity
Slide 50: Key Financials – P&L
Key Financials – P&L * Thousand US $ H1 2019 H1 2018 Q2 2019 Q2 2018 2018 Revenues 540 745 192 379 1,747 Gross Profit 368 196 91 114 295 Operating Loss (9,372) (9,619) (4,703) (4,673) (19,989) Loss (7,895) (10,155) (4,141) (4,769) (20,812)